Published in Sci Signal on March 26, 2013
PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov (2014) 4.81
The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat Med (2013) 3.20
Tyrosine kinase gene rearrangements in epithelial malignancies. Nat Rev Cancer (2013) 1.80
Evading apoptosis in cancer. Trends Cell Biol (2013) 1.17
The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics. Cancer Discov (2015) 1.15
The essential role of p53-up-regulated modulator of apoptosis (Puma) and its regulation by FoxO3a transcription factor in β-amyloid-induced neuron death. J Biol Chem (2014) 1.06
miR-491-5p-induced apoptosis in ovarian carcinoma depends on the direct inhibition of both BCL-XL and EGFR leading to BIM activation. Cell Death Dis (2014) 1.02
BET bromodomain inhibition triggers apoptosis of NF1-associated malignant peripheral nerve sheath tumors through Bim induction. Cell Rep (2013) 1.01
Putting the pieces together: How is the mitochondrial pathway of apoptosis regulated in cancer and chemotherapy? Cancer Metab (2014) 0.97
mTOR kinase inhibitors synergize with histone deacetylase inhibitors to kill B-cell acute lymphoblastic leukemia cells. Oncotarget (2015) 0.92
Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancer. Cancer Lett (2014) 0.91
Evaluation of the BH3-only protein Puma as a direct Bak activator. J Biol Chem (2013) 0.88
High Bak Expression Is Associated with a Favorable Prognosis in Breast Cancer and Sensitizes Breast Cancer Cells to Paclitaxel. PLoS One (2015) 0.86
ERBB3 knockdown induces cell cycle arrest and activation of Bak and Bax-dependent apoptosis in colon cancer cells. Oncotarget (2014) 0.86
hMENA(11a) contributes to HER3-mediated resistance to PI3K inhibitors in HER2-overexpressing breast cancer cells. Oncogene (2015) 0.85
mTORC1 upregulation via ERK-dependent gene expression change confers intrinsic resistance to MEK inhibitors in oncogenic KRas-mutant cancer cells. Oncogene (2015) 0.83
PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim. Breast Cancer Res (2015) 0.83
Cancer therapeutics: Pulling the plug on BCL-X(L). Nat Chem Biol (2013) 0.82
Not just gRASping at flaws: finding vulnerabilities to develop novel therapies for treating KRAS mutant cancers. Cancer Sci (2014) 0.82
The Role of Mir-148a in Cancer. J Cancer (2016) 0.80
A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression. Breast Cancer Res Treat (2014) 0.80
Bim and VDAC1 are hierarchically essential for mitochondrial ATF2 mediated cell death. Cancer Cell Int (2015) 0.79
Evasion of anti-growth signaling: A key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds. Semin Cancer Biol (2015) 0.79
Inhibition of mutant EGFR in lung cancer cells triggers SOX2-FOXO6-dependent survival pathways. Elife (2015) 0.78
HER2 phosphorylates and destabilizes pro-apoptotic PUMA, leading to antagonized apoptosis in cancer cells. PLoS One (2013) 0.77
IMB-6G, a novel N-substituted sophoridinic acid derivative, induces endoplasmic reticulum stress-mediated apoptosis via activation of IRE1α and PERK signaling. Oncotarget (2016) 0.77
Effect of taurine on the proliferation and apoptosis of human hepatocellular carcinoma HepG2 cells. Exp Ther Med (2015) 0.76
Association of BIM Deletion Polymorphism and BIM-γ RNA Expression in NSCLC with EGFR Mutation. Cancer Genomics Proteomics (2016) 0.76
Expression of PUMA in Follicular Granulosa Cells Regulated by FoxO1 Activation During Oxidative Stress. Reprod Sci (2014) 0.76
Identification of a Dual Inhibitor of Janus Kinase 2 (JAK2) and p70 Ribosomal S6 Kinase1 (S6K1) Pathways. J Biol Chem (2015) 0.75
mTOR signaling: new networks for ALL. Blood (2016) 0.75
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med (2005) 25.93
Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science (2001) 23.42
Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell (1997) 21.42
The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol (2008) 20.89
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res (2006) 18.44
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med (2008) 14.47
Cancer. Addiction to oncogenes--the Achilles heal of cancer. Science (2002) 14.20
Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell (2002) 11.09
Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest (2008) 10.74
Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell (2006) 10.29
The expanding role of mitochondria in apoptosis. Genes Dev (2001) 9.91
Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science (1997) 9.58
BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol Cell (2001) 9.33
BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. Mol Cell (2005) 8.73
Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies. Nat Cell Biol (2006) 8.42
Puma is an essential mediator of p53-dependent and -independent apoptotic pathways. Cancer Cell (2003) 7.60
FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene (2005) 7.50
AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell (2011) 6.74
Bid-induced conformational change of Bax is responsible for mitochondrial cytochrome c release during apoptosis. J Cell Biol (1999) 6.58
BAX activation is initiated at a novel interaction site. Nature (2008) 6.07
Expression of the pro-apoptotic Bcl-2 family member Bim is regulated by the forkhead transcription factor FKHR-L1. Curr Biol (2000) 6.05
Membrane binding by tBid initiates an ordered series of events culminating in membrane permeabilization by Bax. Cell (2008) 5.75
Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest (2007) 5.02
The forkhead transcription factor FoxO regulates transcription of p27Kip1 and Bim in response to IL-2. J Immunol (2002) 4.85
BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. Cancer Cell (2007) 4.55
BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med (2007) 4.50
Stepwise activation of BAX and BAK by tBID, BIM, and PUMA initiates mitochondrial apoptosis. Mol Cell (2009) 4.37
Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. Cancer Cell (2002) 4.36
FOXO transcription factors directly activate bim gene expression and promote apoptosis in sympathetic neurons. J Cell Biol (2003) 4.31
Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling. PLoS One (2008) 4.12
Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev (2006) 4.06
Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. Proc Natl Acad Sci U S A (2009) 4.02
BID, BIM, and PUMA are essential for activation of the BAX- and BAK-dependent cell death program. Science (2010) 4.01
FOXO3a-dependent regulation of Puma in response to cytokine/growth factor withdrawal. J Exp Med (2006) 3.78
Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas. PLoS Med (2007) 3.58
BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors. Cancer Discov (2011) 3.34
Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells. Proc Natl Acad Sci U S A (2009) 3.26
Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics. PLoS Med (2007) 3.09
Regulatory phosphorylation of Bim: sorting out the ERK from the JNK. Cell Death Differ (2005) 3.00
Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. Proc Natl Acad Sci U S A (2009) 2.77
Essential role of BAX,BAK in B cell homeostasis and prevention of autoimmune disease. Proc Natl Acad Sci U S A (2005) 2.43
Mimicking the BH3 domain to kill cancer cells. Oncogene (2008) 2.14
Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion. Cancer Res (2007) 2.10
Functional proteomics to dissect tyrosine kinase signalling pathways in cancer. Nat Rev Cancer (2010) 1.97
betaTrCP- and Rsk1/2-mediated degradation of BimEL inhibits apoptosis. Mol Cell (2009) 1.77
Glucose metabolism attenuates p53 and Puma-dependent cell death upon growth factor deprivation. J Biol Chem (2008) 1.58
FoxOs enforce a progression checkpoint to constrain mTORC1-activated renal tumorigenesis. Cancer Cell (2010) 1.58
Phosphorylation of MLL by ATR is required for execution of mammalian S-phase checkpoint. Nature (2010) 1.29
The p53-cathepsin axis cooperates with ROS to activate programmed necrotic death upon DNA damage. Proc Natl Acad Sci U S A (2009) 1.27
A blueprint for advancing genetics-based cancer therapy. Cell (2011) 1.16
Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification. Oncogene (2011) 1.13
Role of survivin in EGFR inhibitor-induced apoptosis in non-small cell lung cancers positive for EGFR mutations. Cancer Res (2010) 1.05
Genetically defining the mechanism of Puma- and Bim-induced apoptosis. Cell Death Differ (2011) 1.04
Alternative splicing of Bim and Erk-mediated Bim(EL) phosphorylation are dispensable for hematopoietic homeostasis in vivo. Cell Death Differ (2012) 0.97
In cancer drug resistance, germline matters too. Nat Med (2012) 0.94
Patterns and rates of exonic de novo mutations in autism spectrum disorders. Nature (2012) 13.71
Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies. Nat Cell Biol (2006) 8.42
Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. Mol Cell Biol (2003) 8.12
Puma is an essential mediator of p53-dependent and -independent apoptotic pathways. Cancer Cell (2003) 7.60
BAX activation is initiated at a novel interaction site. Nature (2008) 6.07
The transcriptional repressor Snail promotes mammary tumor recurrence. Cancer Cell (2005) 5.81
Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis. Nat Cell Biol (2007) 4.67
Stepwise activation of BAX and BAK by tBID, BIM, and PUMA initiates mitochondrial apoptosis. Mol Cell (2009) 4.37
Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. Cancer Cell (2002) 4.36
Global regulation of erythroid gene expression by transcription factor GATA-1. Blood (2004) 4.22
BID, BIM, and PUMA are essential for activation of the BAX- and BAK-dependent cell death program. Science (2010) 4.01
The serine/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor. Genes Dev (2003) 3.79
Slug antagonizes p53-mediated apoptosis of hematopoietic progenitors by repressing puma. Cell (2005) 3.73
Integrated pipeline for mass spectrometry-based discovery and confirmation of biomarkers demonstrated in a mouse model of breast cancer. J Proteome Res (2007) 3.48
Taspase1: a threonine aspartase required for cleavage of MLL and proper HOX gene expression. Cell (2003) 3.35
Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma. Eur Urol (2012) 3.20
A novel doxycycline-inducible system for the transgenic analysis of mammary gland biology. FASEB J (2002) 3.05
Identification of new fluorescent protein fragments for bimolecular fluorescence complementation analysis under physiological conditions. Biotechniques (2006) 2.99
Epigenetic expansion of VHL-HIF signal output drives multiorgan metastasis in renal cancer. Nat Med (2012) 2.95
A targeted proteomics-based pipeline for verification of biomarkers in plasma. Nat Biotechnol (2011) 2.91
CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression. J Clin Invest (2011) 2.90
Hlx is induced by and genetically interacts with T-bet to promote heritable T(H)1 gene induction. Nat Immunol (2002) 2.87
mTOR mediates Wnt-induced epidermal stem cell exhaustion and aging. Cell Stem Cell (2009) 2.74
PUMA regulates intestinal progenitor cell radiosensitivity and gastrointestinal syndrome. Cell Stem Cell (2008) 2.68
Identification of a novel TP53 cancer susceptibility mutation through whole-genome sequencing of a patient with therapy-related AML. JAMA (2011) 2.61
Differential regulation of the transcriptional activities of hypoxia-inducible factor 1 alpha (HIF-1alpha) and HIF-2alpha in stem cells. Mol Cell Biol (2006) 2.56
GATA-1-mediated proliferation arrest during erythroid maturation. Mol Cell Biol (2003) 2.52
Impact of p53 loss on reversal and recurrence of conditional Wnt-induced tumorigenesis. Genes Dev (2003) 2.27
Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network. Clin Cancer Res (2013) 2.26
Proteolysis of MLL family proteins is essential for taspase1-orchestrated cell cycle progression. Genes Dev (2006) 2.20
Computational expression deconvolution in a complex mammalian organ. BMC Bioinformatics (2006) 2.18
The Ets transcription factor Elf5 specifies mammary alveolar cell fate. Genes Dev (2008) 2.13
Lack of sustained regression of c-MYC-induced mammary adenocarcinomas following brief or prolonged MYC inactivation. Cancer Cell (2004) 2.08
Targeted deletion of Puma attenuates cardiomyocyte death and improves cardiac function during ischemia-reperfusion. Am J Physiol Heart Circ Physiol (2006) 2.05
HIF-2alpha deletion promotes Kras-driven lung tumor development. Proc Natl Acad Sci U S A (2010) 1.86
Conditional overexpression of active transforming growth factor beta1 in vivo accelerates metastases of transgenic mammary tumors. Cancer Res (2004) 1.84
JNK1-dependent PUMA expression contributes to hepatocyte lipoapoptosis. J Biol Chem (2009) 1.82
Increased steroidogenic factor-1 dosage triggers adrenocortical cell proliferation and cancer. Mol Endocrinol (2007) 1.81
Regulation of insulin-like growth factor-mammalian target of rapamycin signaling by microRNA in childhood adrenocortical tumors. Cancer Res (2010) 1.80
A pharmacologic inhibitor of the protease Taspase1 effectively inhibits breast and brain tumor growth. Cancer Res (2011) 1.74
Analysis of cell migration using whole-genome expression profiling of migratory cells in the Drosophila ovary. Dev Cell (2006) 1.73
Selection against PUMA gene expression in Myc-driven B-cell lymphomagenesis. Mol Cell Biol (2008) 1.72
Bimodal degradation of MLL by SCFSkp2 and APCCdc20 assures cell cycle execution: a critical regulatory circuit lost in leukemogenic MLL fusions. Genes Dev (2007) 1.71
The huge Package for High-dimensional Undirected Graph Estimation in R. J Mach Learn Res (2012) 1.69
The MIT domain of UBPY constitutes a CHMP binding and endosomal localization signal required for efficient epidermal growth factor receptor degradation. J Biol Chem (2007) 1.69
Six1 expands the mouse mammary epithelial stem/progenitor cell pool and induces mammary tumors that undergo epithelial-mesenchymal transition. J Clin Invest (2009) 1.67
Clinical and molecular characteristics of malignant transformation of low-grade glioma in children. J Clin Oncol (2007) 1.67
Dual molecular imaging for targeting metalloproteinase activity and apoptosis in atherosclerosis: molecular imaging facilitates understanding of pathogenesis. J Nucl Cardiol (2009) 1.60
Notch promotes recurrence of dormant tumor cells following HER2/neu-targeted therapy. J Clin Invest (2015) 1.58
Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy. Clin Cancer Res (2014) 1.57
A secreted Delta1-Fc fusion protein functions both as an activator and inhibitor of Notch1 signaling. J Neurosci Res (2002) 1.56
Persistent parity-induced changes in growth factors, TGF-beta3, and differentiation in the rodent mammary gland. Mol Endocrinol (2002) 1.56
p53 independent induction of PUMA mediates intestinal apoptosis in response to ischaemia-reperfusion. Gut (2006) 1.56
Dual autonomous mitochondrial cell death pathways are activated by Nix/BNip3L and induce cardiomyopathy. Proc Natl Acad Sci U S A (2010) 1.54
Deubiquitylases from genes to organism. Physiol Rev (2013) 1.54
Uncleaved TFIIA is a substrate for taspase 1 and active in transcription. Mol Cell Biol (2006) 1.51
Bcl-X(L) affects Ca(2+) homeostasis by altering expression of inositol 1,4,5-trisphosphate receptors. Proc Natl Acad Sci U S A (2002) 1.51
PET imaging of glutaminolysis in tumors by 18F-(2S,4R)4-fluoroglutamine. J Nucl Med (2011) 1.50
c-Myc transforms human mammary epithelial cells through repression of the Wnt inhibitors DKK1 and SFRP1. Mol Cell Biol (2007) 1.50
Deregulated estrogen receptor alpha expression in mammary epithelial cells of transgenic mice results in the development of ductal carcinoma in situ. Cancer Res (2005) 1.46
Selective roles for antiapoptotic MCL-1 during granulocyte development and macrophage effector function. Blood (2008) 1.45
Identification of Trop-2 as an oncogene and an attractive therapeutic target in colon cancers. Mol Cancer Ther (2008) 1.41
Puma is required for p53-induced depletion of adult stem cells. Nat Cell Biol (2010) 1.41
Krüppel-like factor 4 inhibits tumorigenic progression and metastasis in a mouse model of breast cancer. Neoplasia (2011) 1.39
Functional microarray analysis of mammary organogenesis reveals a developmental role in adaptive thermogenesis. Mol Endocrinol (2002) 1.39
A lysosomal tetraspanin associated with retinal degeneration identified via a genome-wide screen. EMBO J (2004) 1.39
Deletion of Puma protects hematopoietic stem cells and confers long-term survival in response to high-dose gamma-irradiation. Blood (2010) 1.38
A genetic pathway composed of Sox14 and Mical governs severing of dendrites during pruning. Nat Neurosci (2009) 1.38
Isoform-specific requirement for Akt1 in the developmental regulation of cellular metabolism during lactation. Cell Metab (2006) 1.36
Tumor escape in a Wnt1-dependent mouse breast cancer model is enabled by p19Arf/p53 pathway lesions but not p16 Ink4a loss. J Clin Invest (2008) 1.36
Isoform-specific ras activation and oncogene dependence during MYC- and Wnt-induced mammary tumorigenesis. Mol Cell Biol (2006) 1.34
Bax and Bak do not exhibit functional redundancy in mediating radiation-induced endothelial apoptosis in the intestinal mucosa. Int J Radiat Oncol Biol Phys (2008) 1.34
SDF-1/CXCR4 signaling induces pancreatic cancer cell invasion and epithelial-mesenchymal transition in vitro through non-canonical activation of Hedgehog pathway. Cancer Lett (2012) 1.34
Ionizing radiation induces prostate cancer neuroendocrine differentiation through interplay of CREB and ATF2: implications for disease progression. Cancer Res (2008) 1.33
Black phosphorus-monolayer MoS2 van der Waals heterojunction p-n diode. ACS Nano (2014) 1.32
Gene expression profiling of childhood adrenocortical tumors. Cancer Res (2007) 1.32
Hormone-induced protection against mammary tumorigenesis is conserved in multiple rat strains and identifies a core gene expression signature induced by pregnancy. Cancer Res (2006) 1.30
Phosphorylation of MLL by ATR is required for execution of mammalian S-phase checkpoint. Nature (2010) 1.29
Governance of endocytic trafficking and signaling by reversible ubiquitylation. Dev Cell (2012) 1.29
Inactivation of ribosomal protein L22 promotes transformation by induction of the stemness factor, Lin28B. Blood (2012) 1.29
Bax and Bak function as the outer membrane component of the mitochondrial permeability pore in regulating necrotic cell death in mice. Elife (2013) 1.28
ErbB4 splice variants Cyt1 and Cyt2 differ by 16 amino acids and exert opposing effects on the mammary epithelium in vivo. Mol Cell Biol (2009) 1.28
Akt requires glucose metabolism to suppress puma expression and prevent apoptosis of leukemic T cells. J Biol Chem (2010) 1.27